Katherine Reeder-Hayes, MD, MBA, and her colleagues report that women age 66 and older who have HER2-positive breast cancer were less likely than younger women to be treated with trastuzumab (Herceptin), a proven, yet expensive, drug therapy.
Recent work from the laboratory of Liza Makowski, PhD, UNC Lineberger member and assistant professor of nutrition at the UNC Gillings School of Global Public Health, explores two possibilities for breaking the link between obesity and basal-like breast cancer.
UNC Lineberger's annual scientific symposium, “Molecularly Targeted Cancer Therapies from Bench to Bedside,” will be held April 11-12 at The William and Ida Friday Center for Continuing Education. Thanks to event supporters, attendance is free and the cost to for lunch is minimal at $16 per day. Registration is open until 5 p.m. on Wednesday, April 6.
Two UNC Lineberger Comprehensive Cancer Center members - Drs. Deborah Mayer and Barbara Rimer - have been honored with appointments to the National Cancer Moonshot Initiative's Blue Ribbon Panel. They will join a team of cancer experts to provide advice and vision in the implementation of the national program.